2 results
Approved WMOCompleted
Primary (Cohort 1)* To compare the efficacy of zanubrutinib (BGB-3111) vs ibrutinib in subjects with MYD88MUT WMSecondary (Cohort 1) * To further compare the efficacy, clinical benefit, and anti-lymphoma effects of BGB-3111 vs ibrutinib in subjects…
Approved WMOCompleted
OBJECTIVES:To evaluate the effect of TRC101 on the progression of chronic kidney disease and to evaluate the safety profile of TRC101 in CKD patients with metabolic acidosis.